Avantax Advisory Services Inc. Boosts Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Avantax Advisory Services Inc. boosted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 113.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,456 shares of the company's stock after purchasing an additional 14,053 shares during the quarter. Avantax Advisory Services Inc.'s holdings in Hims & Hers Health were worth $640,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Yong Rong HK Asset Management Ltd purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $41,104,000. Principal Financial Group Inc. raised its stake in Hims & Hers Health by 370.3% during the 4th quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company's stock worth $33,024,000 after acquiring an additional 1,075,355 shares in the last quarter. Wellington Management Group LLP lifted its position in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after acquiring an additional 883,230 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Hims & Hers Health during the fourth quarter worth about $18,048,000. Finally, Bank of New York Mellon Corp grew its stake in Hims & Hers Health by 128.7% during the 4th quarter. Bank of New York Mellon Corp now owns 1,244,953 shares of the company's stock worth $30,103,000 after buying an additional 700,500 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Hims & Hers Health Trading Down 0.9 %

Shares of HIMS traded down $0.35 during trading hours on Tuesday, reaching $37.06. The company had a trading volume of 17,472,315 shares, compared to its average volume of 13,881,126. The company has a market capitalization of $8.23 billion, a price-to-earnings ratio of 84.23 and a beta of 1.37. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The firm has a 50 day simple moving average of $39.44 and a 200-day simple moving average of $29.05.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on HIMS shares. Citigroup reissued a "sell" rating and set a $27.00 price objective on shares of Hims & Hers Health in a research report on Thursday, March 6th. Bank of America increased their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research report on Tuesday, March 18th. Needham & Company LLC boosted their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Piper Sandler increased their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Finally, BTIG Research initiated coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $37.31.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the completion of the transaction, the chief executive officer now owns 173,655 shares in the company, valued at approximately $5,900,796.90. The trade was a 42.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 4,152 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 998,244 shares of company stock worth $35,662,485. 17.71% of the stock is owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.